Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors ...
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for …
WEB1 day ago · Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million. The U.S. clinical ...
Genentech buys Regor's next-gen CDK inhibitors for $850M
WEB19 hours ago · Regor announced the results from a Phase1A dose escalation study last December. In a study of 12 patients, it was shown to be safe and well tolerated, as well as showing promising signs of ...
Regor to Sell Portfolio of Breast Cancer Treatment CDK Inhibitors …
WEB1 day ago · Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Genentech takes over Regor’s RGT-419B for US$850m upfront
WEB2 hours ago · With a definitive purchase agreement of Genentech to acquire Chinese Regor Therapeutics Group’s next-generation CDK 4/6 inhibitors including its Phase I candidate RGT-419B for the treatment of breast cancer, the US subsidiary of Swiss Pharma giant Roche AG shows ambitions to attack the current blockbuster medicines Ibrance (Pfizer Inc), Verzenio (Eli Lilly & Company) and Kisqali (Novartis AG).
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Regor Pharmaceuticals (USA) is part of Regor Therapeutics Group, a clinical-stage biotechnology company developing innovative and clinically differentiated medicines to address large unmet needs in oncology, metabolism and auto-immunity. By leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, Regor Therapeutics ...
Genentech To Acquire Portfolio Of Next-generation CDK Inhibitors …
WEB1 day ago · (RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK ...
Regor Therapeutics Group
WEBRegor is a global biopharmaceutical company with a pipeline of innovative drugs for metabolism, oncology and auto-immunity. Read the latest press releases on its clinical trials, presentations and achievements.
Regor Therapeutics Group
WEBBOSTON, Nov. 27, 2023 -- Regor Therapeutics (“Regor”), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that a poster presentation featuring First-in-human Phase 1A study of RGT-419B, will be reported at the San Antonio Breast Cancer Symposium (SABCS), taking ...
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist …
WEBNews provided by. Regor Therapeutics Group Mar 08, 2024, 10:24 ET. Share this article. Share to X. Share this article. Share to X. CAMBRIDGE, Mass., March 8, 2024 …
- Some results have been removed